Three Mid-Cap Stocks with Growth Potential Worth Considering for Long-Term Investors

When it comes to building wealth through equities, mid-cap stocks with growth potential often represent an attractive middle ground between the stability of large-cap companies and the explosive upside of micro-caps. These companies—typically valued between $2 billion and $10 billion—offer compelling opportunities for investors with a longer time horizon, though they do come with elevated risks compared to their larger counterparts. For those willing to embrace volatility in pursuit of substantial long-term returns, three particularly intriguing mid-cap stocks deserve examination: CRISPR Therapeutics (NASDAQ: CRSP), Viking Therapeutics (NASDAQ: VKTX), and e.l.f. Beauty (NYSE: ELF).

CRISPR Therapeutics: Gene Therapy Innovation Meets Patient Access

With a market capitalization hovering around $5.2 billion, CRISPR Therapeutics sits squarely in the mid-cap range, yet the transformative nature of its lead product suggests considerably greater value may eventually be recognized. The company’s flagship offering, Casgevy, represents a remarkable breakthrough—an FDA-approved gene therapy treatment addressing sickle cell disease and transfusion-dependent beta thalassemia. What makes Casgevy particularly noteworthy is that despite its eye-watering price tag exceeding $2 million per treatment, medical experts widely regard it as a cost-effective solution given its one-time application and curative potential.

The primary constraint currently limiting CRISPR’s upward trajectory relates to deployment velocity. Although the company has made measurable progress—approximately 300 patients have already been referred to treatment centers—the rollout pace falls short of some investor expectations. This timing disconnect is particularly notable given that Casgevy secured initial approval for sickle cell disease nearly two years ago. Meanwhile, accumulated losses of $451 million over the trailing nine months underscore the cash burn inherent in the biotech sector. For patient capital investors with conviction in the company’s pipeline, CRISPR presents a potentially undervalued growth opportunity.

Viking Therapeutics: Betting on the GLP-1 Wave

At approximately $4.3 billion in market capitalization, Viking Therapeutics represents perhaps the highest-risk option among this trio, primarily because the company currently lacks any FDA-approved product. Instead, Viking is advancing VK2735, an investigational GLP-1 drug candidate designed to address obesity and weight management. The company recently initiated phase 3 clinical trials—the final major step before regulatory submission—meaning that a multi-year wait looms before investors gain definitive clarity on approval probability.

Earlier trial data, however, provides reason for optimism. Study participants achieved weight loss of up to 14.7% of body mass within just 13 weeks using VK2735, positioning it competitively within the increasingly crowded GLP-1 landscape. Viking is simultaneously developing an oral formulation, though this variant remains earlier in its development timeline. If VK2735 ultimately achieves approval, the revenue potential could be transformative—industry analysts estimate the global GLP-1 market could reach $95 billion by 2030 according to Goldman Sachs research. Such market size has already attracted acquisition interest from major healthcare conglomerates eager to establish GLP-1 capabilities. However, Viking currently generates zero revenue and has accumulated losses exceeding $237 million over the past 12 months, making this investment suitable only for those with high risk tolerance and deep conviction.

e.l.f. Beauty: Brand Strength Offset by Supply Chain Pressures

Unlike its biotech counterparts, e.l.f. Beauty operates an established, revenue-generating business with strong consumer positioning. The company’s strategy of delivering affordable cosmetics to price-conscious younger demographics has proven remarkably effective—in Piper Sandler’s latest teen consumer survey, e.l.f. ranked as the number-one cosmetics brand with 36% mindshare, more than four times the nearest competitor. That brand strength was further bolstered when e.l.f. spent $1 billion to acquire Rhode, a skincare brand founded by influencer Hailey Bieber and similarly popular among younger consumers.

Financial projections reflect this commercial momentum, with e.l.f. guiding for revenues around $1.6 billion and adjusted net income no less than $165 million for its fiscal year. Yet the stock has faced considerable pressure, declining over 40% during recent periods as market participants grapple with the company’s tariff exposure. Approximately 80% of e.l.f.'s product manufacturing occurs in China, making the business particularly vulnerable to U.S.-China trade tensions. Despite these headwinds, e.l.f.'s pricing flexibility—the company has modestly raised prices across many products by $1 while maintaining affordability positioning—may provide adequate buffer against tariff impacts. Should U.S.-China trade relations normalize and tariff concerns dissipate, e.l.f.'s stock could re-rate significantly upward.

Comparing Risk-Return Profiles Across These Mid-Cap Growth Candidates

Each of these mid-cap stocks with growth potential occupies a distinct position along the risk-reward spectrum. CRISPR offers the most tangible near-term catalyst—an approved product with known clinical efficacy requiring only deployment acceleration. Viking presents the highest potential upside should clinical trials succeed, but carries correspondingly elevated execution risk given its pre-revenue status. Meanwhile, e.l.f. Beauty combines established profitability with a near-term catalyst (tariff resolution) capable of driving material appreciation.

For investors seeking exposure to innovative, growing companies with valuations that haven’t yet fully priced in their long-term potential, this trio collectively represents compelling long-term entry points. The optimal selection among them depends entirely on individual risk tolerance and conviction in the specific business narratives. What unites all three is the possibility of substantial multi-year returns for investors willing to maintain their conviction through inevitable volatility.